<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553978</url>
  </required_header>
  <id_info>
    <org_study_id>WD-1603-1004</org_study_id>
    <nct_id>NCT04553978</nct_id>
  </id_info>
  <brief_title>A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomised, 2-treatment, 2-period, 2-sequence, Single Oral Dose, Corssover Comparative PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hong Kong WD Pharmaceutical Co., Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hong Kong WD Pharmaceutical Co., Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral&#xD;
      dose, crossover comparative Pharmacokinetics study of WD-1603 extended-release&#xD;
      carbidopa/levodopa tablets in normal, healthy, adult human subjects under fasting conditions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, balanced, randomized, two-treatment, two-period, two-sequence, single&#xD;
      oral dose, crossover comparative Pharmacokinetics study of WD-1603 extended-release&#xD;
      carbidopa/levodopa tablets in normal, healthy, adult human subjects under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 18, 2020</start_date>
  <completion_date type="Anticipated">March 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Blood samples will be collected at designed timepoints pre and post dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Blood samples will be collected at designed timepoints pre and post dose</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After an overnight fasting of at least 10 hours, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.&#xD;
Subjects will be in sitting posture or ambulatory posture for the first 04 hours post-dose unless medically necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least 03 hours after taking dinner, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.&#xD;
Subjects will be in supine/lateral recumbent positions post-dose till morning when they will wake up unless medically necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WD-1603</intervention_name>
    <description>WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive).&#xD;
&#xD;
          2. Having a Body Mass Index (BMI) between 18.5 to 29.9 (both inclusive), calculated as&#xD;
             weight in kg / height in m2, a minimum body weight of 50.0 kg.&#xD;
&#xD;
          3. Not having any significant disease or clinically significant abnormal findings during&#xD;
             screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG&#xD;
             and X-ray chest (P/A view) recordings.&#xD;
&#xD;
          4. Able to understand and comply with the study procedures, in the opinion of the&#xD;
             principal investigator.&#xD;
&#xD;
          5. Able to give voluntary written informed consent for participation in the trial.&#xD;
&#xD;
          6. In case of female subjects:&#xD;
&#xD;
               -  Surgically sterilized at least 6 months prior to study participation&#xD;
&#xD;
             or&#xD;
&#xD;
               -  If of child bearing potential is willing to use a suitable and effective double&#xD;
                  barrier contraceptive method or intra uterine device during the study.&#xD;
&#xD;
             And&#xD;
&#xD;
               -  Serum Pregnancy test must be negative.&#xD;
&#xD;
          7. Female must also be willing to abstain from ovum donation from check-in of period-I&#xD;
             and for at least 28 days after the last study drug administration.&#xD;
&#xD;
          8. Female subjects of non-childbearing potential must be either post-menopausal&#xD;
             (post-menopausal is defined as being amenorrheic for at least 1 year without another&#xD;
             cause and a follicle-stimulating hormone [FSH] level â‰¥26 IU/L) or surgically sterile&#xD;
             (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation).&#xD;
&#xD;
          9. Male subjects with female sexual partners of childbearing potential must be willing to&#xD;
             use and willing to continue using medically acceptable contraception (true abstinence,&#xD;
             vasectomy, or male condom for subjects plus an additional method of contraception for&#xD;
             their female partners) from check-in of period-I until 28 days following the last&#xD;
             administration of study drug.&#xD;
&#xD;
         10. Men must also be willing to abstain from sperm donation from check-in of period-I and&#xD;
             for at least 28 days after the last study drug administration.&#xD;
&#xD;
         11. Subjects should be literate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity or idiosyncratic reaction to Carbidopa or Levodopa or any of&#xD;
             the excipients or any related drug.&#xD;
&#xD;
          2. History or presence of any disease or condition which might compromise the&#xD;
             haemopoietic, renal, hepatic, endocrine, pulmonary, cardiovascular, immunological,&#xD;
             dermatological, gastrointestinal system, and central nervous system with dyskinesia,&#xD;
             depression, suicidal thought, or any other body system.&#xD;
&#xD;
          3. History or presence of ophthalmic diseases such as wide angle glaucoma and ocular&#xD;
             hypertension.&#xD;
&#xD;
          4. Ingestion of a medicine (prescribed &amp; over the counter (OTC) medication including&#xD;
             herbal remedies and MAO inhibitors) at any time within 30 days before check-in in&#xD;
             Period I. In any such case subject selection will be at the discretion of the&#xD;
             Principal Investigator.&#xD;
&#xD;
          5. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or&#xD;
             NSAIDs induced urticaria.&#xD;
&#xD;
          6. Use of any recreational drugs or history of drug addiction or testing positive in&#xD;
             pre-study drug scans.&#xD;
&#xD;
          7. A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol&#xD;
             consumption of more than 14 standard drinks per week for men and more than 7 standard&#xD;
             drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of&#xD;
             wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or&#xD;
             consumption of alcohol or alcoholic products within 48 hours prior to check-in of&#xD;
             Period I.&#xD;
&#xD;
          8. Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from&#xD;
             smoking during the study.&#xD;
&#xD;
          9. The presence of clinically significant abnormal laboratory values during screening.&#xD;
&#xD;
         10. History or presence of psychiatric disorders.&#xD;
&#xD;
         11. A history of difficulty in donating blood.&#xD;
&#xD;
         12. Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first&#xD;
             dose of study medication.&#xD;
&#xD;
         13. Receipt of an investigational medicinal product or participation in a drug research&#xD;
             study within a period of 90 days prior to the first dose of study medication**.&#xD;
&#xD;
             ** If investigational medicinal product is received within 90 days where there is no&#xD;
             blood loss except safety lab testing, subject can be included considering 10&#xD;
             half-lives duration of investigational medicinal product received.&#xD;
&#xD;
         14. A positive hepatitis screen including hepatitis B surface antigen and/or HCV&#xD;
             antibodies.&#xD;
&#xD;
         15. A positive test result for HIV (1 &amp;/or 2) antibody.&#xD;
&#xD;
         16. An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to&#xD;
             receiving the study medicine in period I. In any such case subject selection will be&#xD;
             at the discretion of the Principal Investigator.&#xD;
&#xD;
         17. Consumption of grapefruit or grapefruit products within 72 hours prior to check-in of&#xD;
             period-I.&#xD;
&#xD;
         18. Difficulty in swallowing oral solid dosage form like tablets or capsules.&#xD;
&#xD;
         19. Nursing mothers (females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 13, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

